Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656759 · ClinicalTrials.gov registry record · Phase 2
Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
A Phase 2 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT01656759 is a Phase 2 study that has completed, run by Rush University Medical Center. The registered enrollment target is 73 participants.
The verdict
NCT01656759, a Phase 2 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.
Interventions
- DRUG Evicel Fibrin Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656759
The ClinicalTrials.gov registry entry for NCT01656759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evicel Fibrin Spray is the first listed.
NCT01656759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01656759 about?
NCT01656759 is a clinical study titled "Use of a Novel Fibrin Sealant in Total Knee Arthroplasty". Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.
What is the current status of trial NCT01656759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2012-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01656759?
The interventions under investigation include: Evicel Fibrin Spray (DRUG).
Who is sponsoring clinical trial NCT01656759?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.